EDIT earnings call for the period ending June 30, 2020.
News & Analysis: Editas Medicine
A rumored merger has investors excited, although details are scarce.
It's possible. But is it probable?
These two cutting-edge gene-editing companies are locked in tight competition.
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
Which of these companies that are developing cutting-edge gene-editing technologies is the better buy for investors?
It could soon be Editas' time to shine.
These four companies have tremendous growth potential going into 2020.
Editas has more favorable terms for its collaborations with big pharma companies, but it still has a long way to go.
EDIT earnings call for the period ending March 31, 2020.